Rising femtech start-up poised to improve women’s health

September 27, 2024 – Hyivy Health (“Hyivy”), a FACIT-backed medtech company, announced the closing of a seed financing round to advance their game-changing Pelvic Health Rehabilitation System. With seed capital secured, Hyivy will complete clinical trials and seek regulatory approval allowing their technology to benefit patients recovering from gynecological and colorectal cancers. Hyivy is a member of FACIT’s portfolio of women-led entrepreneurial ventures creating science-based jobs in Ontario.

Given the scarcity of early seed capital for Ontario life sciences innovations, FACIT‘s role in the ecosystem is critical to help advance translation so cancer breakthroughs can reach patients sooner. FACIT joined existing and new investors to continue to support Hyivy with an investment from its Compass Rose Oncology Fund, which is guided by an Ontario First commercialization mandate. As start-ups advance through key milestones, FACIT helps drive innovative cancer solutions to ensure patients lead longer and healthier lives.

Congratulations to Hyivy on this important achievement and advancement for women’s health.

Read the company’s announcement here.
To learn more about Hyivy Health and related news, please click here.

---

About FACIT        
FACIT is an award-winning commercialization venture firm that builds companies with entrepreneurs to accelerate oncology innovation, with a portfolio that has attracted more than $1.6 billion in investment to Ontario. Blending industry experience, capital and the unsurpassed clinician-scientist network of its strategic partner the Ontario Institute for Cancer Research (OICR), FACIT capitalizes on the province’s investment in research and healthcare to the benefit of the local economy and patients worldwide. Cancer Breakthroughs. Realized. facit.ca